Is GILD a good stock to buy?
We came across a bullish thesis on Gilead Sciences, Inc. on r/investing_discussion by Variant_Invest
In this article, we will summarize the bulls’ thesis on GILD. Gilead Sciences, Inc.’s share was trading at $133.73 as of May 26th. GILD’s trailing and forward P/E were 18.19 and 15.22 respectively according to Yahoo Finance.
Pressmaster/ Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States and internationally. GILD is being mischaracterized by the market as a slow-growth HIV cash cow despite a rapidly shifting pipeline that increasingly skews toward long-acting HIV innovation and a credible oncology expansion, suggesting the current valuation underappreciates its multi-platform earnings durability. 15 AI Stocks That Are Quietly Making Investors Rich Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential The HIV franchise is not in structural decline but is transitioning through lenacapavir, a twice-yearly injectable for treatment and prevention, with PURPOSE 1 and PURPOSE 2 trials demonstrating 100% and 96% efficacy, positioning it as a potential paradigm shift in adherence and prevention economics. Oncology provides the second pillar with Trodelvy showing traction in triple-negative breast cancer and additional bladder cancer expansion, while broader pipeline assets, despite prior setbacks like magrolimab, still create meaningful optionality that is currently priced near zero by the market.